These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16222784)

  • 1. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.
    Jadhav PR; Agersø H; Tornøe CW; Gobburu JV
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):609-34. PubMed ID: 16967346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.
    Tornøe CW; Overgaard RV; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2005 Aug; 22(8):1247-58. PubMed ID: 16078134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2004 Apr; 21(4):574-84. PubMed ID: 15139513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
    Tornøe CW; Agersø H; Senderovitz T; Nielsen HA; Madsen H; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Jun; 63(6):648-64. PubMed ID: 17096678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
    Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO
    Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics.
    Olafsdottir HK; Leander J; Almquist J; Jirstrand M
    AAPS J; 2018 Aug; 20(5):88. PubMed ID: 30069613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of uncertainty parameters estimated by different population PK software and methods.
    Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: Degarelix--a potential new therapy for prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    IDrugs; 2006 Aug; 9(8):565-72. PubMed ID: 16871466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degarelix acetate for the treatment of prostate cancer.
    Klotz L
    Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An implementation of the Expectation-Maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME.
    Yates JW
    Comput Methods Programs Biomed; 2009 Oct; 96(1):49-62. PubMed ID: 19410328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.